Developing a new treatment for osteoarthritis by targeting a specific signaling pathway
Targeting the PTH1R Signaling Pathway for Osteoarthritis Therapy by a Novel Disruptor Peptide
This study is looking for safer and easier treatments for osteoarthritis by exploring how certain signals in cartilage work, with the hope of finding ways to stop cartilage damage and help it heal, making life better for people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10915488 on NIH RePORTER |
What this research studies
This research focuses on creating new anabolic agents that are less toxic and easier to use for treating osteoarthritis (OA). It investigates the complex signaling pathways in cartilage that contribute to OA progression, particularly the role of the parathyroid hormone receptor (PTH1R) and its interaction with beta-catenin. By understanding how these pathways work, the research aims to develop therapies that can prevent cartilage degeneration and promote cartilage regeneration, potentially improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with osteoarthritis who are seeking new treatment options.
Not a fit: Patients with osteoarthritis who are not responsive to hormonal therapies or those with advanced joint degeneration may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for osteoarthritis, improving the quality of life for patients suffering from this condition.
How similar studies have performed: Previous research has shown promise in targeting similar signaling pathways for osteoarthritis treatment, indicating that this approach may be viable.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Wang, Bin — Thomas Jefferson University
- Study coordinator: Wang, Bin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.